University of Tübingen’s immuno-oncology spinout Immatics has undertaken a reverse merger with special purpose acquisition company Arya Sciences to list in the US.

Immatics, a Germany-based cancer immunotherapies developer spun out of University of Tübingen, has executed a reverse merger with special purpose acquisition company Arya Sciences Acquisition to list on the Nasdaq Capital Market.
Shares opened at $15.05 on Thursday but have continued to drop and closed at $14.40 yesterday, giving Immatics a market cap of $5.64bn. It is trading under the ticker symbol IMTX.
Proceeds from the transaction amounted to approximately $253m, consisting of $149m held in Arya’s trust…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in